Sanofi (ENXTPA: SAN) is expected to report Q2 earnings on Aug. 1. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Sanofi's revenues will shrink -1.9% and EPS will wane -6.4%.

The average estimate for revenue is $11.03 billion. On the bottom line, the average EPS estimate is $1.76.

Revenue details
 Last quarter, Sanofi reported revenue of $10.33 billion. GAAP reported sales were 12% lower than the prior-year quarter's $11.91 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $1.56. GAAP EPS of $0.97 for Q1 were 47% lower than the prior-year quarter's $1.84 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 68.9%, 170 basis points worse than the prior-year quarter. Operating margin was 19.5%, 650 basis points worse than the prior-year quarter. Net margin was 12.3%, 810 basis points worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $46.61 billion. The average EPS estimate is $7.65.

Investor sentiment

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Sanofi is outperform, with an average price target of $102.52.

Can your portfolio provide you with enough income to last through retirement? You'll need more than Sanofi. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.